The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? The ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

Investors and vaccine makers like Moderna MRNA and Johnson & Johnson JNJ have reasons to cheer the latest update concerning the application of COVID-19 booster shots. In an effort to combat the ...